Search

GA in Practice Background

Editorial Feature:

GA in Practice

How data and personal experience are evolving the treatment of geographic atrophy.

Talking to Patients About Treatment Risks

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Show Description +

How do you counsel patients about safety risks when beginning complement inhibition therapy for GA? Moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, discuss how they explain the risk-benefit profile of complement inhibition to patients, the persistent gap in referring-physician education, and the considerations that guide their choice between avacincaptad pegol (Izervay, Astellas) and pegcetacoplan (Syfovre, Biogen), particularly in monocular patients.

Posted: 7/01/2026

Keywords:

Geographic Atrophy (GA)

•

Patient Education

•

Safety

•

risk

•

complement inhibition

•

risk-benefit profile

•

Referral Network

•

avacincaptad pegol

•

astellas

•

izervay

•

Pegcetacoplan

•

syfovre

•

Apellis

•

Biogen

•

Monocular

Up Next

GA in the Presence of Dense Cataract, Followed by CNV Development

GA in the Presence of Dense Cataract, Followed by CNV Development

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Delayed Complement Inhibition Therapy per Patient Request

Delayed Complement Inhibition Therapy per Patient Request

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Multimodal Imaging for Biomarker Detection in GA Patients

Multimodal Imaging for Biomarker Detection in GA Patients

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Talking to Patients About Treatment Risks

Talking to Patients About Treatment Risks

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Back to All Videos

Talking to Patients About Treatment Risks

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

How do you counsel patients about safety risks when beginning complement inhibition therapy for GA? Moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, discuss how they explain the risk-benefit profile of complement inhibition to patients, the persistent gap in referring-physician education, and the considerations that guide their choice between avacincaptad pegol (Izervay, Astellas) and pegcetacoplan (Syfovre, Biogen), particularly in monocular patients.

Posted: 7/01/2026

Keywords:

Geographic Atrophy (GA)

•

Patient Education

•

Safety

•

risk

•

complement inhibition

•

risk-benefit profile

•

Referral Network

•

avacincaptad pegol

•

astellas

•

izervay

•

Pegcetacoplan

•

syfovre

•

Apellis

•

Biogen

•

Monocular

Please log in to leave a comment.